Saturday 17 October 2026
Export SYRE’s income statement to Excel — free account
Spyre Therapeutics, Inc.
SYRE Healthcare Biotechnology
Spyre Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $886,000.00, down 62.0% from fiscal 2022. In the quarter to June 2026, EPS grew 26.5% and free cash flow fell 50.1%, each against the same quarter a year earlier.
79.90
0.20
−0.25%
Follow SYRE
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 3 | — | — | — | — | 2 | 2 | — |
P/E ratio |
— | — | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | 140.04 | 15.24 | 14.79 | — | — | 23.52 | 15.64 | 9.67 |
Altman Z-Score |
— | — | (3.82) | (10.38) | 1.92 | — | — | 6.12 | 6.26 | 5.40 |
P/FCF ratio |
— | — | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | (4.89) | (20.59) | (6.06) | — | — | 3.64 | 7.45 | 17.85 |
P/Operating CF |
— | — | (4.76) | (1.96) | (16.21) | — | — | (21.66) | (13.86) | (10.28) |
Beneish M-Score |
— | — | — | (2.18) | — | — | — | (4.80) | 0.73 | (3.04) |
P/B ratio |
— | — | 0.00 | 0.71 | 3.72 | — | — | 2.31 | 1.62 | 0.71 |
Price to Tangible BV |
— | — | 0.00 | 0.71 | 3.72 | — | — | 2.31 | 1.62 | 0.71 |
EV/Sales |
— | — | (181.86) | (8.68) | 10.38 | — | — | 12.28 | 5.97 | (4.05) |
EV/EBITDA |
— | — | 0.79 | 0.24 | 0.00 | — | — | 0.00 | 0.00 | 0.87 |
EV/Operating CF |
— | — | 1.92 | 0.25 | (4.08) | — | — | (2.53) | (1.26) | 1.00 |
EV/FCF |
— | — | 1.93 | 0.25 | (4.04) | — | — | (2.50) | (1.23) | 0.98 |
Quick Ratio |
12.89 | 11.16 | 10.61 | 3.83 | 4.66 | 8.90 | 3.92 | 7.31 | 9.48 | 16.32 |
Current Ratio |
13.25 | 11.26 | 10.68 | 4.25 | 4.91 | 9.11 | 4.06 | 7.49 | 9.77 | 16.75 |
Net Debt/EBITDA |
3.61 | 2.89 | 1.41 | 0.67 | 1.48 | 1.82 | 0.89 | 1.63 | 1.84 | 2.93 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.03 | 0.14 | 0.00 | 0.00 | 0.06 | 0.08 | 0.09 |
Operating CF/Net income |
1.09 | 0.76 | 0.29 | 0.96 | 0.82 | 0.94 | 0.84 | 0.73 | 0.90 | 0.87 |
Capex/Depreciation |
— | 0.00 | 0.49 | (0.02) | (0.22) | (4.00) | 3.73 | 1.41 | (1.91) | (0.91) |
| (33.69%) | (115.22%) | (1,371.79%) | (124.87%) | (58.81%) | (80.93%) | (122.74%) | (75.32%) | (48.08%) | (106.47%) | |
| (22.39%) | (43.78%) | (164.06%) | (92.58%) | (48.46%) | (66.09%) | (97.26%) | (66.28%) | (44.24%) | (41.05%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (45,519.74%) | 0.00% |
Return on Tangible Assets |
(21.58%) | (37.52%) | (109.45%) | (164.92%) | (79.00%) | (58.20%) | (133.70%) | (65.75%) | (54.24%) | (34.41%) |
Average Days of Receivables |
— | — | 0.00 | 58.77 | 15.87 | — | — | 28.16 | 215.84 | 95.82 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 10,102.03% | 2,515.20% | 304.55% | 0.00% | 0.00% | 944.42% | 438.33% | 392.03% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 4,508.58% | 1,225.03% | 145.79% | 0.00% | 0.00% | 324.90% | 193.39% | 181.31% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 2,897.86% | 305.32% | 42.89% | 0.00% | 0.00% | 110.08% | 47.88% | 26.38% |
Graham Net Nets |
— | — | 1.24 | 1.17 | 0.23 | — | — | 0.43 | 0.61 | 1.39 |
Graham Number |
— | — | 14.94 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | (351.12%) | (239.79%) | (21.05%) | — | — | (28.44%) | (33.46%) | (184.68%) |
Free Cash Flow Yield |
— | — | (67.37%) | (225.89%) | (17.38%) | — | — | (20.91%) | (31.01%) | (42.57%) |
Revenue per Share |
0.00 | 0.00 | 0.13 | 0.69 | 7.13 | 0.00 | 0.00 | 4.67 | 8.60 | 11.82 |
Operating CF per Share |
(2.64) | (3.35) | (14.49) | (23.77) | (20.43) | (35.49) | (51.40) | (38.65) | (40.68) | (48.10) |
Capex per Share |
0.00 | 0.00 | 0.07 | (0.01) | (0.22) | (2.00) | (1.17) | (0.51) | (1.02) | (0.54) |
Free Cash Flow per Share |
(2.64) | (3.35) | (14.42) | (23.79) | (20.64) | (37.50) | (52.57) | (39.16) | (41.70) | (48.64) |
Cash per Share |
11.81 | 12.82 | 49.19 | 16.53 | 35.41 | 68.52 | 56.30 | 89.46 | 83.13 | 162.12 |
Shareholders Equity per Share |
11.17 | 11.01 | 26.68 | 14.92 | 31.92 | 65.50 | 47.01 | 80.96 | 83.19 | 160.75 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
11.17 | 11.01 | 26.68 | 14.92 | 31.92 | 65.50 | 47.01 | 80.96 | 83.19 | 160.75 |
Free Cash Flow |
(169.25) | (157.41) | (99.43) | (80.18) | (54.29) | (80.05) | (67.18) | (32.61) | (25.23) | (19.05) |
Working Capital |
719.10 | 554.41 | 309.55 | 47.60 | 78.75 | 133.35 | 56.15 | 66.43 | 49.36 | 62.46 |
Capital Expenditures |
— | — | 0.48 | (0.04) | (0.57) | (4.28) | (1.49) | (0.42) | (0.62) | (0.21) |
Net Current Asset Value |
715.24 | 517.79 | 183.69 | 41.42 | 72.91 | 128.00 | 51.40 | 66.36 | 49.25 | 62.33 |
EV/EBIT |
— | — | 0.79 | 0.24 | 0.00 | — | — | 0.00 | 0.00 | 0.86 |
Capex to Sales |
— | — | (0.54) | 0.02 | 0.03 | 0.00 | 0.00 | 0.11 | 0.12 | 0.05 |
Price to Operating Income |
— | — | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
— | 0.00 | 0.00 | 0.51 | 0.56 | 0.19 | (0.17) | (0.29) | 0.38 | 0.39 |
Cash ROIC |
(11.50%) | (14.04%) | (19.00%) | (75.63%) | (30.66%) | (27.98%) | (50.89%) | (22.98%) | (25.07%) | (15.06%) |
Accounts Receivable Turnover |
— | — | 0.00 | 3.91 | 33.61 | — | — | 2.30 | 2.42 | 3.18 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | — | — | 0.60 | 0.56 | — | — | 1.69 | 2.15 | 1.46 |
Average Payables |
4.79 | 0.78 | 0.79 | 2.00 | 2.79 | 2.70 | 1.91 | 0.53 | 0.28 | 0.17 |
Average Assets |
693.13 | 475.17 | 206.50 | 90.54 | 135.77 | 122.40 | 80.46 | 66.91 | 61.57 | 52.86 |
Average Common Equity |
460.70 | 180.54 | 24.70 | 67.12 | 111.89 | 99.96 | 63.75 | 58.88 | 56.65 | 20.38 |
Columns are period end dates